Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323068 | 0.83 | USP2 (0.42) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL799912 | 0.77 | KDM4E (0.37) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL25005479 | 0.75 | KDM4E (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL31722944 | 0.75 | KDM4E (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL15578278 | 0.75 | USP2 (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL16028550 | 0.75 | KDM4E (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL15538067 | 0.74 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14671190 | 0.74 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2591925 | 0.72 | KDM4E (0.37) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL31347705 | 0.72 | HCRTR2 (0.38) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513283-B2 | Spiro substituted compounds as angiogenesis inhibitors | ADVENCHEN LABORATORIES, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120165371-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2012-06-28 | — | — | US | disclosed |
| US-8163923-B2 | Benzyl 1-((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)methyl)cyclo-propylcarbamate; cancers associated with protein tyrosine kinases | ADVENCHEN LABORATORIES, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8148532-B2 | Benzyl 1-((4-(1H-indol-5-ylamino)-6-methoxyquinolin-7-yloxy)methyl)cyclopropylcarbamate; cancers associated with protein tyrosine kinases | CHEN GUOQING PAUL (US) | 2012-04-03 | — | — | US | disclosed |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | disclosed |
| US-20080227811-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165371-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | TEK, KDR, TIE1 | KDM4E 3218/4885USP2 4757/4885ALDH1A1 588/4885 |
| US-20080227811-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | TEK, KDR, TIE1 | KDM4E 3218/4885USP2 4757/4885ALDH1A1 588/4885 |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | TEK, KDR, TIE1 | KDM4E 3218/4885USP2 4757/4885ALDH1A1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.